High-dose administration of EGFR-TKIs for NSCLC patients: a literature review

High-dose EGFR-TKIs have been used as an exploratory therapeutic strategy to overcome the limitations of the standard-dose regimen in the treatment of EGFR-mutant NSCLC, particularly in patients with CNS metastases. Available clinical evidence suggests that high-dose TKIs confer certain therapeutic efficacy and manageable safety profiles, with a small proportion of patients experiencing ≥3 grade adverse events, such as rash, nausea,diarrhea, aminotransferase rise, leukopenia.However, the evidence is limited by the predominance of single-center retrospective studies, small sample sizes, heterogeneous patient populations and short follow-up periods. Further large-scale, multicenter studies with long-term follow-up are needed to define more clearly the efficacy, safety, and appropriate clinical role of high-dose EGFR-TKI therapy.